Meeting
2019 ASCO Annual Meeting
Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.
Authors
Kamran A. Ahmed
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Kamran A. Ahmed , Youngchul Kim , Sachin M. Apte , Hye Sook Chon , Jing-Yi Chern , Jose Conejo-Garcia , Daniel Celestino Fernandez , Mitchel Hoffman , Sungjune Kim , Cesar Lam , Michael E. Montejo , Mian M. Shahzad , Robert Michael Wenham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03614949
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS5596)
DOI
10.1200/JCO.2019.37.15_suppl.TPS5596
Abstract #
TPS5596
Poster Bd #
418a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu
Poster
2021 ASCO Annual Meeting
A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).
First Author: Kai Sun
Poster
2019 ASCO Annual Meeting
KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
First Author: Ronnie Shapira-Frommer
First Author: Ana Oaknin